Isn't it ironic? Just a couple of years after paying a fine for the illegal promotion of Evista as a breast cancer prevention drug, manufacturer Eli Lilly has finally gained FDA approval for the use of the popular osteoporosis drug for prevention of breast cancer in postmenopausal women. Evista, or raloxifene, can now be prescribed for postmenopausal women at high risk of breast cancer, as well as for postmenopausal women with osteoporosis.
The medication is a SERM (selective estrogen ...
Read more »With Breast Cancer Comics by Dash Shaw It's been five years since I finished... Read more »
Saving money while saving your life sounds like a strange juxtaposition of ideas, doesn’t it?... Read more »
A recent BBC News story reports on a growing controversy involving breast cancer care guidelines... Read more »
You’ve been through every drug the oncologist has in his or her bag of tricks, yet nothing has... Read more »
I’m usually pretty upbeat when I’m writing a SharePost. I mean, why not? I have a family who... Read more »
ORLANDO, Fla. (Ivanhoe Broadcast News) -- More than 211,000 women are diagnosed with breast cancer each year. Many of them have advanced disease... Read summary »
A federal advisory panel voted not to recommend the approval of the medication Avastin as a treatment for breast cancer. The panel voted 5-4 that... Read summary »
Several new studies shed light on issues that affect breast cancer treatment and medication use. In studies presented at a symposium on breast... Read summary »
INDIANAPOLIS, Ind. (Ivanhoe Broadcast News) -- When breast cancer spreads to other parts of the body, it can be deadly. Now, a new drug stops... Read summary »
After completing treatment for breast cancer, women face a host of new challenges, including anxiety about recurrence. Carolyn Vachani, an oncology... Read summary »